Base de dados : MEDLINE
Pesquisa : F03.700.750.600 [Categoria DeCS]
Referências encontradas : 3872 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 388 ir para página                         

  1 / 3872 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29281504
[Au] Autor:Rosenbaum L
[Ad] Endereço:Dr. Rosenbaum is a national correspondent for the Journal.
[Ti] Título:Swallowing a Spy - The Potential Uses of Digital Adherence Monitoring.
[So] Source:N Engl J Med;378(2):101-103, 2018 01 11.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Adesão à Medicação/psicologia
Aplicativos Móveis
Sistemas de Alerta
[Mh] Termos MeSH secundário: Doença das Coronárias/tratamento farmacológico
Feminino
Seres Humanos
Masculino
Meia-Idade
Esquizofrenia Paranoide/tratamento farmacológico
Telemetria
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180118
[Lr] Data última revisão:
180118
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171228
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMp1716206


  2 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29220388
[Au] Autor:Morera-Fumero AL; Díaz-Mesa E; Abreu-Gonzalez P; Fernandez-Lopez L; Guillen-Pino F
[Ad] Endereço:Departamento de Medicina Interna, Dermatología y Psiquiatría, Facultad de Ciencias de la Salud, Universidad de la Laguna (ULL), La Laguna, Santa Cruz de Tenerife, España.
[Ti] Título:A three-month longitudinal study of changes in day/night serum total antioxidant capacity in paranoid schizophrenia.
[So] Source:PLoS One;12(12):e0189348, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Free radicals and an oxidant/antioxidant imbalance have been involved in the schizophrenia pathophysiology. The total antioxidant capacity (TAC) is a measure of the antioxidant capacity of a system. Day/night changes are a biological characteristic of hormones such as melatonin or cortisol. There is little information about TAC day/night changes in schizophrenia patients. The aim of this research is to study if there are day/night changes in serum TAC levels of schizophrenia patients. Thirty-two DSM-IV schizophrenia paranoid patients were studied. Blood was sampled at 12:00 and 00:00 h at admission, discharge and three months after hospital discharge (TMAHD). TAC results are expressed as mmol of Trolox/L. Patients did not have day/night TAC differences at admission (12:00: 0.67±0.12 vs. 00:00: 0.61±0.14, p>0.14) or discharge (12:00: 0.65±0.15 vs. 00:00: 0.65±0.12, p>0.99). At TMHD, patients had significantly higher TAC levels at midday than midnight (12:00: 0.83±0.10 vs. 00:00: 0.74±0.12, p<0.006) as it has been reported in healthy subjects. There were no significant TAC differences at 12.00 and 00:00 between admission and discharge. At TMAHD, patients had significantly higher TAC levels than at admission and discharge, both at 12:00 and 00:00 h. In conclusion, the absence of day/night serum TAC changes when clinically relapsed and the normalization of day/night serum TAC changes at TMHD can be considered as a biological marker of schizophrenia evolution.
[Mh] Termos MeSH primário: Antioxidantes/metabolismo
Esquizofrenia Paranoide/sangue
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
Meia-Idade
Admissão do Paciente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189348


  3 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29210250
[Au] Autor:Dute J
[Ti] Título:European Court of Human Rights.
[So] Source:Eur J Health Law;23(5):525-37, 2016 Dec.
[Is] ISSN:0929-0273
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Prisioneiros/legislação & jurisprudência
[Mh] Termos MeSH secundário: Internação Compulsória de Doente Mental/legislação & jurisprudência
Alemanha
Hepatite/tratamento farmacológico
Dependência de Heroína/tratamento farmacológico
Seres Humanos
Masculino
Tratamento de Substituição de Opiáceos
Federação Russa
Esquizofrenia Paranoide
Tuberculose/tratamento farmacológico
Ucrânia
[Pt] Tipo de publicação:JOURNAL ARTICLE; LEGAL CASES
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171228
[Lr] Data última revisão:
171228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  4 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953679
[Au] Autor:Zhang F; Kanzali P; Rubin V; Paras C; Goldman J
[Ad] Endereço:aDepartment of Internal Medicine, Brookdale University Hospital and Medical Center, Brooklyn bRoss University School of Medicine, Portsmouth, Dominica cDivision of Endocrinology, Brookdale University Hospital and Medical Center, Brooklyn, New York.
[Ti] Título:Neuroleptic malignant syndrome with thyroid disorder: An unusual case report.
[So] Source:Medicine (Baltimore);96(39):e8191, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Neuroleptic malignant syndrome (NMS) is a life threatening neurologic emergency associated with neuroleptic or antipsychotic agent use. NMS is rarely related to thyroid disease. PATIENT CONCERNS: We report a case of NMS in a 66-year-old male with past medical history of paranoid schizophrenia on chlorpromazine, diabetes, hypertension and asthma, who presented with a humeral fracture after a fall. Patient developed hyperpyrexia, altered consciousness, autonomic instability, elevated serum creatine kinase (CK) without rigidity. DIAGNOSES: CT head and workup for infection were negative. Electroencephalogram (EEG) showed generalized slow wave activity. Ultrasound revealed a large goiter with nodules. INTERVENTIONS: Chlorpromazine was stopped due to concern of NMS. Patient was treated with cooling, fluid and electrolyte maintenance. OUTCOMES: Patient slowly improved and CK level normalized. Thyroid-stimulating hormone (TSH) level trended down from 10.2 mIU/L to 0.02 mIU/L. Patient was discharged with aripiprazole. LESSONS: Hypothyroidism predisposes patients to NMS by altering central dopaminergic systems. The typical symptoms may be masked by hypothyroidism. Thyroid dysfunction should be excluded in all patients with NMS. Discontinuing antipsychotic agents decreases TSH levels which maybe due to the negative feedback of dopaminergic activity. This is the first case report describing dramatic changes in TSH after discontinuing chlorpromazine in NMS.
[Mh] Termos MeSH primário: Aripiprazol
Clorpromazina
Hipotireoidismo
Síndrome Maligna Neuroléptica
Esquizofrenia Paranoide
Nódulo da Glândula Tireoide/diagnóstico por imagem
[Mh] Termos MeSH secundário: Idoso
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Aripiprazol/administração & dosagem
Aripiprazol/efeitos adversos
Clorpromazina/administração & dosagem
Clorpromazina/efeitos adversos
Creatina Quinase/análise
Diagnóstico Diferencial
Substituição de Medicamentos/métodos
Hidratação/métodos
Seres Humanos
Hipotireoidismo/complicações
Hipotireoidismo/diagnóstico
Hipotireoidismo/terapia
Masculino
Síndrome Maligna Neuroléptica/diagnóstico
Síndrome Maligna Neuroléptica/etiologia
Síndrome Maligna Neuroléptica/fisiopatologia
Síndrome Maligna Neuroléptica/terapia
Esquizofrenia Paranoide/complicações
Esquizofrenia Paranoide/tratamento farmacológico
Tireotropina/análise
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 82VFR53I78 (Aripiprazole); 9002-71-5 (Thyrotropin); EC 2.7.3.2 (Creatine Kinase); U42B7VYA4P (Chlorpromazine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008191


  5 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28541090
[Au] Autor:Leucht S; Leucht C; Huhn M; Chaimani A; Mavridis D; Helfer B; Samara M; Rabaioli M; Bächer S; Cipriani A; Geddes JR; Salanti G; Davis JM
[Ad] Endereço:From the Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany; the Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, U.K.; the Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; the Ins
[Ti] Título:Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
[So] Source:Am J Psychiatry;174(10):927-942, 2017 Oct 01.
[Is] ISSN:1535-7228
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Antipsychotic drug efficacy may have decreased over recent decades. The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate which trial characteristics have changed over the years and which are moderators of drug-placebo efficacy differences. METHOD: The search included multiple electronic databases. The outcomes were overall efficacy (primary outcome); responder and dropout rates; positive, negative, and depressive symptoms; quality of life; functioning; and major side effects. Potential moderators of efficacy were analyzed by meta-regression. RESULTS: The analysis included 167 double-blind randomized controlled trials with 28,102 mainly chronic participants. The standardized mean difference (SMD) for overall efficacy was 0.47 (95% credible interval 0.42, 0.51), but accounting for small-trial effects and publication bias reduced the SMD to 0.38. At least a "minimal" response occurred in 51% of the antipsychotic group versus 30% in the placebo group, and 23% versus 14% had a "good" response. Positive symptoms (SMD 0.45) improved more than negative symptoms (SMD 0.35) and depression (SMD 0.27). Quality of life (SMD 0.35) and functioning (SMD 0.34) improved even in the short term. Antipsychotics differed substantially in side effects. Of the response predictors analyzed, 16 trial characteristics changed over the decades. However, in a multivariable meta-regression, only industry sponsorship and increasing placebo response were significant moderators of effect sizes. Drug response remained stable over time. CONCLUSIONS: Approximately twice as many patients improved with antipsychotics as with placebo, but only a minority experienced a good response. Effect sizes were reduced by industry sponsorship and increasing placebo response, not decreasing drug response. Drug development may benefit from smaller samples but better-selected patients.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtornos Psicóticos/tratamento farmacológico
Esquizofrenia Paranoide/tratamento farmacológico
Esquizofrenia/tratamento farmacológico
Psicologia do Esquizofrênico
[Mh] Termos MeSH secundário: Teorema de Bayes
Depressão/psicologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Seres Humanos
Análise Multivariada
Pacientes Desistentes do Tratamento
Transtornos Psicóticos/psicologia
Qualidade de Vida
Esquizofrenia Paranoide/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1176/appi.ajp.2017.16121358


  6 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28399309
[Au] Autor:Bebbington P; Freeman D
[Ad] Endereço:UCL Division of Psychiatry, Faculty of Brain Sciences, Tottenham Court Road, London, UK.
[Ti] Título:Transdiagnostic Extension of Delusions: Schizophrenia and Beyond.
[So] Source:Schizophr Bull;43(2):273-282, 2017 03 01.
[Is] ISSN:1745-1701
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Delusion is central to the conceptualization, definition, and identification of schizophrenia. However, in current classifications, the presence of delusions is neither necessary nor sufficient for the diagnosis of schizophrenia, nor is it sufficient to exclude the diagnosis of some other psychiatric conditions. Partly as a consequence of these classification rules, it is possible for delusions to exist transdiagnostically. In this article, we evaluate the extent to which this happens, and in what ways the characteristics of delusions vary according to diagnostic context. We were able to examine their presence and form in delusional disorder, affective disorder, obsessive-compulsive disorder, borderline personality disorder, and dementia, in all of which they have an appreciable presence. There is some evidence that the mechanisms of delusion formation are, at least to an extent, shared across these disorders. This transdiagnostic extension of delusions is an argument for targeting them therapeutically in their own right. However there is a dearth of research to enable the rational transdiagnostic deployment of either pharmacological or psychological treatments.
[Mh] Termos MeSH primário: Transtornos Psicóticos Afetivos/classificação
Transtorno da Personalidade Borderline/classificação
Comorbidade
Delusões/classificação
Demência/classificação
Transtorno Obsessivo-Compulsivo/classificação
Esquizofrenia Paranoide/classificação
Esquizofrenia/classificação
[Mh] Termos MeSH secundário: Transtornos Psicóticos Afetivos/epidemiologia
Transtorno da Personalidade Borderline/epidemiologia
Delusões/epidemiologia
Demência/epidemiologia
Seres Humanos
Transtorno Obsessivo-Compulsivo/epidemiologia
Esquizofrenia/epidemiologia
Esquizofrenia Paranoide/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1093/schbul/sbw191


  7 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28374702
[Au] Autor:Uranova NA; Kolomeets NS; Vikhreva OV; Zimina IS; Rakhmanova VI; Orlovskaya DD
[Ad] Endereço:Mental Health Research Centre, Moscow, Russia.
[Ti] Título:[Ultrastructural changes of myelinated fibers in the brain in continuous and attack-like paranoid schizophrenia].
[Ti] Título:Ul'trastrukturnye izmeneniya mielinovykh volokon v golovnom mozge pri nepreryvnotekushchei i pristupoobraznoi paranoidnoi shizofrenii..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(2):104-109, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: Previously the authors have reported the ultrastructural pathology of myelinated fibers (MF) in the brain in schizophrenia. The aim of the present study was to compare the effect of disease course on ultrastructural changes of MF. MATERIAL AND METHODS: Postmortem electron microscopic morphometric study of MF was performed in the prefrontal cortex, caudate nucleus and hippocampus in 19 cases of paranoid schizophrenia. Fourteen cases of continuous schizophrenia, 5 cases of attack-like schizophrenia and 25 normal matched control cases were studied. The proportion (percentage) of pathological MF was estimated in the prefrontal cortex, layer 5, CA3 area of hippocampus, pyramidal layer, and in the head of the caudate nucleus. RESULTS: The percentage of MF having axonal atrophy and swelling of periaxonal oligodendrocyte process was significantly higher in both continuous and attack-like schizophrenia in all brain structures studied as compared to the control group. In the hippocampus and caudate nucleus, this parameter was increased significantly in attack-like schizophrenia as compared to continuous schizophrenia. In the prefrontal cortex. The percentage of the pathological MF having signs of deformation and destruction of myelin sheaths increased significantly only in continuous schizophrenia as compared to the control group. CONCLUSION: MF pathology is similar in attack-like and continuous paranoid schizophrenia but differ by the degree of severity of pathological MF. Abnormalities in MF contribute to the disconnectivity between the prefrontal cortex, caudate nucleus and hippocampus.
[Mh] Termos MeSH primário: Núcleo Caudado/ultraestrutura
Hipocampo/ultraestrutura
Fibras Nervosas Mielinizadas/ultraestrutura
Córtex Pré-Frontal/ultraestrutura
Esquizofrenia Paranoide/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Atrofia
Autopsia
Axônios/patologia
Feminino
Seres Humanos
Masculino
Microscopia Eletrônica
Meia-Idade
Oligodendroglia/ultraestrutura
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro201711721104-109


  8 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262165
[Au] Autor:Teo DC; Abraham AM; Peh AL
[Ad] Endereço:Department of Psychological Medicine, Changi General Hospital, 2 Simei Street 3, 529889, Singapore. Electronic address: david_teo@cgh.com.sg.
[Ti] Título:Folie à deux and Fregoli syndrome with greater severity in the 'secondary' - A case report.
[So] Source:Asian J Psychiatr;25:254-255, 2017 Feb.
[Is] ISSN:1876-2026
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Folie à deux and Fregoli syndrome are rarely seen in clinical practice. We present a case in which these rare syndromes co-occur. Remarkably, in this case the 'secondary' develops a more serious illness course than the 'primary' and reciprocally induces a de novo Fregoli delusion in the 'primary'. This case discusses how socio-cultural factors, such as interdependent family dynamics, could have precipitated this rare variant of folie à deux. It also highlights the importance of making culturally-sensitive formulations for treatment.
[Mh] Termos MeSH primário: Relações Mãe-Filho
Esquizofrenia Paranoide/fisiopatologia
Transtorno Paranoide Compartilhado/fisiopatologia
[Mh] Termos MeSH secundário: Crianças Adultas
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE


  9 / 3872 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28188811
[Au] Autor:Morera-Fumero AL; Díaz-Mesa E; Abreu-Gonzalez P; Fernandez-Lopez L; Cejas-Mendez MD
[Ad] Endereço:Departamento de Medicina Interna, Dermatología y Psiquiatría, Facultad de Ciencias de la Salud, Universidad de la Laguna (ULL), La Laguna, Santa Cruz de Tenerife, Spain; Consultoria Psiquiátrica SC, Santa Cruz de Tenerife, Spain. Electronic address: amorera@ull.es.
[Ti] Título:Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia.
[So] Source:Prog Neuropsychopharmacol Biol Psychiatry;75:207-212, 2017 Apr 03.
[Is] ISSN:1878-4216
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:There are day/night and seasonal changes in biological markers such as melatonin and cortisol. Controversial changes in serum S100B protein levels have been described in schizophrenia. We aim studying whether serum S100B levels present day/night variations in schizophrenia patients and whether S100B levels are related to psychopathology. Sixty-five paranoid schizophrenic inpatients participated in the study. Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and discharge. Blood was drawn at 12:00 (midday) and 00:00 (midnight) hours at admission and discharge. Sixty-five healthy subjects matched by age, gender and season acted as control group. At admission and discharge patients had significantly higher serum S100B concentrations at midday and midnight than healthy subjects. At admission, patients showed a day/night variation of S100B levels, with higher S100B levels at 12:00 than at 00:00h (143.7±26.3pg/ml vs. 96.9±16.6pg/ml). This day/night difference was not present in the control group. Midday and midnight S100B at admission decreased when compared to S100B at discharge (midday, 143.7±26.3 vs. 83.0±12, midnight 96.9±16.6 vs. 68.6±14.5). There was a positive correlation between the PANSS positive subscale and S100B concentrations at admission. This correlation was not present at discharge. CONCLUSIONS: acute paranoid schizophrenia inpatients present a day/night change of S100B serum levels at admission that disappears at discharge. The correlation between serum S100B concentrations and the PANSS positive scores at admission as well as the decrease of S100B at discharge may be interpreted as an acute biological response to the clinical state of the patients.
[Mh] Termos MeSH primário: Ritmo Circadiano/fisiologia
Subunidade beta da Proteína Ligante de Cálcio S100/sangue
Esquizofrenia Paranoide/sangue
Esquizofrenia Paranoide/fisiopatologia
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Análise de Variância
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Masculino
Meia-Idade
Escalas de Graduação Psiquiátrica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (S100 Calcium Binding Protein beta Subunit)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170212
[St] Status:MEDLINE


  10 / 3872 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28082298
[Au] Autor:Darby RR; Laganiere S; Pascual-Leone A; Prasad S; Fox MD
[Ad] Endereço:Berenson-Allen Center for Non-Invasive Brain Stimulation and Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA rdarby@bidmc.harvard.edu.
[Ti] Título:Finding the imposter: brain connectivity of lesions causing delusional misidentifications.
[So] Source:Brain;140(2):497-507, 2017 02.
[Is] ISSN:1460-2156
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:SEE MCKAY AND FURL DOI101093/AWW323 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Focal brain injury can sometimes lead to bizarre symptoms, such as the delusion that a family member has been replaced by an imposter (Capgras syndrome). How a single brain lesion could cause such a complex disorder is unclear, leading many to speculate that concurrent delirium, psychiatric disease, dementia, or a second lesion is required. Here we instead propose that Capgras and other delusional misidentification syndromes arise from single lesions at unique locations within the human brain connectome. This hypothesis is motivated by evidence that symptoms emerge from sites functionally connected to a lesion location, not just the lesion location itself. First, 17 cases of lesion-induced delusional misidentifications were identified and lesion locations were mapped to a common brain atlas. Second, lesion network mapping was used to identify brain regions functionally connected to the lesion locations. Third, regions involved in familiarity perception and belief evaluation, two processes thought to be abnormal in delusional misidentifications, were identified using meta-analyses of previous functional magnetic resonance imaging studies. We found that all 17 lesion locations were functionally connected to the left retrosplenial cortex, the region most activated in functional magnetic resonance imaging studies of familiarity. Similarly, 16 of 17 lesion locations were functionally connected to the right frontal cortex, the region most activated in functional magnetic resonance imaging studies of expectation violation, a component of belief evaluation. This connectivity pattern was highly specific for delusional misidentifications compared to four other lesion-induced neurological syndromes (P < 0.0001). Finally, 15 lesions causing other types of delusions were connected to expectation violation (P < 0.0001) but not familiarity regions, demonstrating specificity for delusion content. Our results provide potential neuroanatomical correlates for impaired familiarity perception and belief evaluation in patients with delusional misidentifications. More generally, we demonstrate a mechanism by which a single lesion can cause a complex neuropsychiatric syndrome based on that lesion's unique pattern of functional connectivity, without the need for pre-existing or hidden pathology.
[Mh] Termos MeSH primário: Lesões Encefálicas/complicações
Mapeamento Encefálico
Encéfalo/patologia
Esquizofrenia Paranoide/diagnóstico
Esquizofrenia Paranoide/etiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Encéfalo/diagnóstico por imagem
Feminino
Seres Humanos
Processamento de Imagem Assistida por Computador
Imagem por Ressonância Magnética
Masculino
Metanálise como Assunto
Motivação
Testes Neuropsicológicos
Escalas de Graduação Psiquiátrica
Recognição (Psicologia)
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE
[do] DOI:10.1093/brain/aww288



página 1 de 388 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde